The evolutionary analysis of emerging low frequency HIV-1 CXCR4 using variants through time-an ultra-deep approach

PLoS Computational Biology

Volumn 6, Issue 12, 2010, Pages

  Archer, John ^a   Rambaut, Andrew ^b   Taillon, Bruce E ^c   Richard Harrigan, P ^d,e   Lewis, Marilyn ^f   Robertson, David L ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

^c British Columbia Centre for Excellence in HIV/AIDS ^*  (United States)

^d BRITISH COLUMBIA CENTRE FOR EXCELLENCE IN HIV AIDS   (Canada)

^e UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^f PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DISEASES; PATIENT TREATMENT; POPULATION STATISTICS; VIRUSES;

CORECEPTORS; CURRENT MAPPING; DATA LOSS; LARGE-SCALES; LIFE-SCIENCES; LOWER FREQUENCIES; MAPPING SOFTWARES; PYROSEQUENCING; SEQUENCE DATA; ULTRA DEEPS;

MAPPING;

CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR4; LAMIVUDINE; MARAVIROC; ZIDOVUDINE; CXCR4 PROTEIN, HUMAN; CYCLOHEXANE DERIVATIVE; HUMAN IMMUNODEFICIENCY VIRUS FUSION INHIBITOR; TRIAZOLE DERIVATIVE;

ANTIVIRAL ACTIVITY; ANTIVIRAL RESISTANCE; ARTICLE; COMPUTER PREDICTION; DATA ANALYSIS SOFTWARE; DRUG RESPONSE; DRUG TREATMENT FAILURE; GENETIC VARIABILITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MALE; MICROBIAL DIVERSITY; MOLECULAR EVOLUTION; NONHUMAN; PHYLOGENY; POPULATION GENETIC STRUCTURE; PYROSEQUENCING; QUANTITATIVE ANALYSIS; SEQUENCE ALIGNMENT; TREATMENT OUTCOME; VIRAL TROPISM; VIRUS LOAD; VIRUS MUTATION; ALGORITHM; BIOLOGY; COMPUTER PROGRAM; DRUG EFFECT; GENETICS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; METHODOLOGY; PATHOGENICITY; SEQUENCE ANALYSIS; VIROLOGY;

HUMAN IMMUNODEFICIENCY VIRUS 1;

ALGORITHMS; COMPUTATIONAL BIOLOGY; CYCLOHEXANES; GENETIC VARIATION; HIV FUSION INHIBITORS; HIV INFECTIONS; HIV-1; HUMANS; RECEPTORS, CXCR4; SEQUENCE ALIGNMENT; SEQUENCE ANALYSIS, RNA; SOFTWARE; TRIAZOLES; VIRAL TROPISM;

EID: 78651228163     PISSN: 1553734X     EISSN: 15537358     Source Type: Journal    
DOI: 10.1371/journal.pcbi.1001022     Document Type: Article

References (42)

1. Margulies M, Egholm M, Altman WE, Attiya S, Bader JS, et al. (2005) Genome sequencing in microfabricated high-density picolitre reactors. Nature 437: 376-380.
2. Brockman W, Alvarez P, Young S, Garber M, Giannoukos G, et al. (2008) Quality scores and SNP detection in sequencing-by-synthesis systems. Genome Res 18: 763-770.
3. Wang C, Mitsuya Y, Gharizadeh B, Ronaghi M, Shafer RW (2007) Characterization of mutation spectra with ultra-deep pyrosequencing: application to HIV-1 drug resistance. Genome Res 17: 1195-1201.
4. Pop M, Salzberg SL (2008) Bioinformatics challenges of new sequencing technology. Trends Genet 24: 142-149.
5. Shendure J, Hanlee J (2008) Next-generation DNA sequencing. Nat Biotech 26: 1135-1145.
6. Archer J, Braverman MS, Taillon BE, Desany B, James I, et al. (2009) Detection of low-frequency pretherapy chemokine (CXC motif) receptor 4 (CXCR4)-using HIV-1 with ultra-deep pyrosequencing. AIDS 23: 1209-1218.
7. Bruselles A, Rozera G, Bartolini B, Prosperi M, Del Nonno F, et al. (2009) Use of massive parallel pyrosequencing for near full-length characterization of a unique HIV Type 1 BF recombinant associated with a fatal primary infection. AIDS Res Hum Retroviruses 25: 937-942.
8. Le T, Chiarella J, Simen BB, Hanczaruk B, Egholm M, et al. (2009) Lowabundance HIV drug-resistant viral variants in treatment-experienced persons correlate with historical antiretroviral use. PLoS One 4: e6079.
9. Palmer S, Kearney M, Maldarelli F, Halvas EK, Bixby CJ, et al. (2005) Multiple, linked human immunodeficiency virus type 1 drug resistance mutations in treatment-experienced patients are missed by standard genotype analysis. J Clin Microbiol 43: 406-413.
10. Rozera G, Abbate I, Bruselles A, Vlassi C, D'Offizi G, et al. (2009) Massively parallel pyrosequencing highlights minority variants in the HIV-1 env quasispecies deriving from lymphomonocyte sub-populations. Retrovirology 6: 15.
11. Tsibris AM, Korber B, Arnaout R, Russ C, Lo CC, et al. (2009) Quantitative deep sequencing reveals dynamic HIV-1 escape and large population shifts during CCR5 antagonist therapy in vivo. PLoS One 4: e5683.
12. Li H, Ruan J, Durbin R (2008) Mapping short DNA sequencing reads and calling variants using mapping quality scores. Genome Res 18: 1851-1858.
13. Altschul SF, Madden TL, Schaffer AA, Zhang J, Zhang Z, et al. (1997) Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. Nucleic Acids Res 25: 3389-3402.
14. Buhler J (2001) Efficient large-scale sequence comparison by locality-sensitive hashing. Bioinformatics 17: 419-428.
15. Kent WJ (2002) BLAT-the BLAST-like alignment tool. Genome Res 12: 656-664.
16. Homer N, Merriman B, Nelson SF (2009) BFAST: an alignment tool for large scale genome resequencing. PLoS One 4: e7767.
17. Langmead B, Trapnell C, Pop M, Salzberg SL (2009) Ultrafast and memoryefficient alignment of short DNA sequences to the human genome. Genome Biol 10: R25.
18. Rumble SM, Lacroute P, Dalca AV, Fiume M, Sidow A, et al. (2009) SHRiMP: accurate mapping of short color-space reads. PLoS Comput Biol 5: e1000386.
19. Starcich BR, Hahn BH, Shaw GM, McNeely PD, Modrow S, et al. (1986) Identification and characterization of conserved and variable regions in the envelope gene of HTLV-III/LAV, the retrovirus of AIDS. Cell 45: 637-648.
20. Bjorndal A, Deng H, Jansson M, Fiore JR, Colognesi C, et al. (1997) Coreceptor usage of primary human immunodeficiency virus type 1 isolates varies according to biological phenotype. J Virol 71: 7478-7487.
21. Connor RI, Sheridan KE, Ceradini D, Choe S, Landau NR (1997) Change in coreceptor use correlates with disease progression in HIV-1-infected individuals. J Exp Med 185: 621-628.
22. Koot M, van Leeuwen R, de Goede RE, Keet IP, Danner S, et al. (1999) Conversion rate towards a syncytium-inducing (SI) phenotype during different stages of human immunodeficiency virus type 1 infection and prognostic value of SI phenotype for survival after AIDS diagnosis. J Infect Dis 179: 254-258.
23. Cardozo T, Kimura T, Philpott S, Weiser B, Burger H, et al. (2007) Structural basis for coreceptor selectivity by the HIV type 1 V3 loop. AIDS Res Hum Retroviruses 23: 415-426.
24. Jensen MA, Li FS, van't Wout AB, Nickle DC, Shriner D, et al. (2003) Improved coreceptor usage prediction and genotypic monitoring of R5-to-X4 transition by motif analysis of human immunodeficiency virus type 1 env V3 loop sequences. J Virol 77: 13376-13388.
25. Soriano V, Perno CF, Kaiser R, Calvez V, Gatell JM, et al. (2009) When and how to use maraviroc in HIV-infected patients. AIDS 23: 2377-2385.
26. Jetzt AE, Yu H, Klarmann GJ, Ron Y, Preston BD, et al. (2000) High rate of recombination throughout the human immunodeficiency virus type 1 genome. J Virol 74: 1234-1240.
27. Korber B, Gaschen B, Yusim K, Thakallapally R, Kesmir C, et al. (2001) Evolutionary and immunological implications of contemporary HIV-1 variation. Br Med Bull 58: 19-42.
28. Malim MH, Emerman M (2001) HIV-1 sequence variation: drift, shift, and attenuation. Cell 104: 469-472.
29. Wei X, Ghosh SK, Taylor ME, Johnson VA, Emini EA, et al. (1995) Viral dynamics in human immunodeficiency virus type 1 infection. Nature 373: 117-122.
30. Dorr P, Westby M, Dobbs S, Griffin P, Irvine B, et al. (2005) Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity. Antimicrob Agents Chemother 49: 4721-4732.
31. Cooper DA, Heera J, Goodrich J, Tawadrous M, Saag M, et al. (2010) Maraviroc versus Efavirenz, both in combination with zidovudine-lamivudine, for the treatment of antiretroviral-naive subjects with CCR5-tropic HIV-1 infection. J Infect Dis 201: 803-813.
32. Rosen O, Sharon M, Quadt-Akabayov SR, Anglister J (2006) Molecular switch for alternative conformations of the HIV-1 V3 region: implications for phenotype conversion. Proc Natl Acad Sci U S A 103: 13950-13955.
33. Smith TF, Waterman MS (1981) Identification of common molecular subsequences. J Mol Biol 147: 195-197.
34. Edgar RC (2004) MUSCLE: multiple sequence alignment with high accuracy and high throughput. Nucleic Acids Res 32: 1792-1797.
35. Crooks GE, Hon G, Chandonia JM, Brenner SE (2004) WebLogo: a sequence logo generator. Genome Res 14: 1188-1190.
36. Guindon S, Gascuel O (2003) A simple, fast, and accurate algorithm to estimate large phylogenies by maximum likelihood. Syst Biol 52: 696-704.
37. Archer J, Robertson DL (2007) CTree: comparison of clusters between phylogenetic trees made easy. Bioinformatics 23: 2952-2953.
38. Archer J, Robertson DL (2007) Understanding the diversification of HIV-1 groups M and O. Aids 21: 1693-1700.
39. Rambaut A, Robertson DL, Pybus OG, Peeters M, Holmes EC (2001) Human immunodeficiency virus. Phylogeny and the origin of HIV-1. Nature 410: 1047-1048.
40. Anisimova M, Gascuel O (2006) Approximate likelihood-ratio test for branches: A fast, accurate, and powerful alternative. Syst Biol 55: 539-552.
41. Westby M, Lewis M, Whitcomb J, Youle M, Pozniak AL, et al. (2006) Emergence of CXCR4-using human immunodeficiency virus type 1 (HIV-1) variants in a minority of HIV-1-infected patients following treatment with the CCR5 antagonist maraviroc is from a pretreatment CXCR4-using virus reservoir. J Virol 80: 4909-4920.
42. Swenson LC, Moores A, Low AJ, Thielen A, Dong W, et al. (2010) Improved detection of CXCR4-using HIV by V3 genotyping: application of populationbased and ''deep'' sequencing to plasma RNA and proviral DNA. J Acquir Immune Defic Syndr 54: 506-510